On April 13, 2016, Yao, Li published a patent.Quality Control of N-(3-Aminophenyl)acrylamide The title of the patent was Preparation of pyrimidine derivatives as EGFR and ALK kinase inhibitors for treatment of cancer. And the patent contained the following:
The present invention discloses compounds represented by formula I [wherein R1 and R2 are selected from H, halogen, cyano, etc.; R3 is selected from H, halogen, substituted or unsubstituted C1-C6 alkyl and C3-C8 cycloalkyl; R are independently selected from H, halo, CN, OH, NH2, etc.; X and Y are independently selected from CH, C-halo, C-CN, N, etc. with the proviso that at least one of X and Y is N; and so on] or their pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs, and preparation method and pharmaceutical application thereof. For example, compound II was prepared in a multi-step synthesis. The compounds of the present invention have good kinase inhibitory activity, particularly on EGFR and ALK kinases and mutants thereof, and have good prospect in medicine for the treatment of cancer. (assay data given). The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Quality Control of N-(3-Aminophenyl)acrylamide
The Article related to preparation pyrimidine derivative human egfr alk kinase inhibitors, treatment cancer antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of N-(3-Aminophenyl)acrylamide
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics